Acne Vulgaris - Pipeline Review, H2 2017

Date: October 10, 2017
Pages: 201
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A1FF4E1E589EN
Leaflet:

Download PDF Leaflet

Acne Vulgaris - Pipeline Review, H2 2017
Acne Vulgaris - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acne Vulgaris - Pipeline Review, H2 2017, provides an overview of the Acne Vulgaris (Dermatology) pipeline landscape.

Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. Risk factors include adolescence, hair gels or oil-based cosmetics, sports equipment such as helmet straps rubbing and occluding skin. Treatment includes antibiotics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acne Vulgaris - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Acne Vulgaris (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acne Vulgaris (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 12, 20, 9, 1, 17, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Acne Vulgaris (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acne Vulgaris (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Acne Vulgaris (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acne Vulgaris (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acne Vulgaris (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acne Vulgaris (Dermatology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acne Vulgaris (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acne Vulgaris (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Acne Vulgaris - Overview
Acne Vulgaris - Therapeutics Development
Acne Vulgaris - Therapeutics Assessment
Acne Vulgaris - Companies Involved in Therapeutics Development
Acne Vulgaris - Drug Profiles
Acne Vulgaris - Dormant Projects
Acne Vulgaris - Discontinued Products
Acne Vulgaris - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Acne Vulgaris, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Acne Vulgaris - Pipeline by 3SBio Inc, H2 2017
Acne Vulgaris - Pipeline by Almirall SA, H2 2017
Acne Vulgaris - Pipeline by Biomar Microbial Technologies, H2 2017
Acne Vulgaris - Pipeline by BioPharmX Inc, H2 2017
Acne Vulgaris - Pipeline by Blueberry Therapeutics Ltd, H2 2017
Acne Vulgaris - Pipeline by Braintree Laboratories Inc, H2 2017
Acne Vulgaris - Pipeline by Brickell Biotech Inc, H2 2017
Acne Vulgaris - Pipeline by Cassiopea SpA, H2 2017
Acne Vulgaris - Pipeline by Celtaxsys Inc, H2 2017
Acne Vulgaris - Pipeline by Common Pharma Inc, H2 2017
Acne Vulgaris - Pipeline by Cutanea Life Sciences Inc, H2 2017
Acne Vulgaris - Pipeline by Deltanoid Pharmaceuticals Inc, H2 2017
Acne Vulgaris - Pipeline by Dermira Inc, H2 2017
Acne Vulgaris - Pipeline by Eligo Bioscience SAS, H2 2017
Acne Vulgaris - Pipeline by ELORAC Inc, H2 2017
Acne Vulgaris - Pipeline by Ensol Biosciences Inc, H2 2017
Acne Vulgaris - Pipeline by Foamix Pharmaceuticals Ltd, H2 2017
Acne Vulgaris - Pipeline by Galderma SA, H2 2017
Acne Vulgaris - Pipeline by Helix BioMedix Inc, H2 2017
Acne Vulgaris - Pipeline by Hovione FarmaCiencia SA, H2 2017
Acne Vulgaris - Pipeline by Innovation Pharmaceuticals Inc, H2 2017
Acne Vulgaris - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017
Acne Vulgaris - Pipeline by LEO Pharma A/S, H2 2017
Acne Vulgaris - Pipeline by Melinta Therapeutics Inc, H2 2017
Acne Vulgaris - Pipeline by Novabiotics Ltd, H2 2017
Acne Vulgaris - Pipeline by Novan Inc, H2 2017
Acne Vulgaris - Pipeline by Novartis AG, H2 2017
Acne Vulgaris - Pipeline by Paratek Pharmaceuticals Inc, H2 2017
Acne Vulgaris - Pipeline by Pfizer Inc, H2 2017
Acne Vulgaris - Pipeline by Phagelux Inc, H2 2017
Acne Vulgaris - Pipeline by Phosphagenics Ltd, H2 2017
Acne Vulgaris - Pipeline by Photocure ASA, H2 2017
Acne Vulgaris - Pipeline by Promius Pharma LLC, H2 2017
Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals Inc, H2 2017
Acne Vulgaris - Pipeline by Realm Therapeutics Plc, H2 2017
Acne Vulgaris - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2017
Acne Vulgaris - Pipeline by Sol-Gel Technologies Ltd, H2 2017
Acne Vulgaris - Pipeline by Sun Pharmaceutical Industries Ltd, H2 2017
Acne Vulgaris - Pipeline by Taro Pharmaceutical Industries Ltd, H2 2017
Acne Vulgaris - Pipeline by Thesan Pharmaceuticals Inc, H2 2017
Acne Vulgaris - Pipeline by Valeant Pharmaceuticals International Inc, H2 2017
Acne Vulgaris - Pipeline by Vyome Biosciences Pvt Ltd, H2 2017
Acne Vulgaris - Pipeline by XBiotech Inc, H2 2017
Acne Vulgaris - Dormant Projects, H2 2017
Acne Vulgaris - Dormant Projects, H2 2017 (Contd..1), H2 2017
Acne Vulgaris - Dormant Projects, H2 2017 (Contd..2), H2 2017
Acne Vulgaris - Dormant Projects, H2 2017 (Contd..3), H2 2017
Acne Vulgaris - Dormant Projects, H2 2017 (Contd..4), H2 2017
Acne Vulgaris - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Acne Vulgaris, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

3SBio Inc
Almirall SA
Biomar Microbial Technologies
BioPharmX Inc
Blueberry Therapeutics Ltd
Braintree Laboratories Inc
Brickell Biotech Inc
Cassiopea SpA
Celtaxsys Inc
Common Pharma Inc
Cutanea Life Sciences Inc
Deltanoid Pharmaceuticals Inc
Dermira Inc
Eligo Bioscience SAS
ELORAC Inc
Ensol Biosciences Inc
Foamix Pharmaceuticals Ltd
Galderma SA
Helix BioMedix Inc
Hovione FarmaCiencia SA
Innovation Pharmaceuticals Inc
Lee's Pharmaceutical Holdings Ltd
LEO Pharma A/S
Melinta Therapeutics Inc
Novabiotics Ltd
Novan Inc
Novartis AG
Paratek Pharmaceuticals Inc
Pfizer Inc
Phagelux Inc
Phosphagenics Ltd
Photocure ASA
Promius Pharma LLC
Provectus Biopharmaceuticals Inc
Realm Therapeutics Plc
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Sol-Gel Technologies Ltd
Sun Pharmaceutical Industries Ltd
Taro Pharmaceutical Industries Ltd
Thesan Pharmaceuticals Inc
Valeant Pharmaceuticals International Inc
Vyome Biosciences Pvt Ltd
XBiotech Inc
Skip to top


Ask Your Question

Acne Vulgaris - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: